Seeking Alpha

Teva falls on Goldman downgrade

  • Goldman downgrades Teva Pharmaceutical (TEVA -1.8%) to Sell, price target is $40.
  • The company's focus on pipeline rebuilding has left it "relatively quiet" in an environment "awash with accretive deal activity," analyst Jami Rubin notes.
  • Of course there's also the whole generic Copaxone problem which Rubin says will leave the company "facing fewer options with respect to capital allocation."
  • Previously: Patent invalidation dents TEVA's plan to transition Copaxone patients to longer-acting formulation.
From other sites
Comments (2)
  • doc47
    , contributor
    Comments (1368) | Send Message
    Teva continue to be "Dead money" even covered calls and an average dividend can't generate a decent return in a bull market.
    30 Jul 2013, 09:43 AM Reply Like
  • Nikola Sesic
    , contributor
    Comments (36) | Send Message
    Maybe i don't understand a part of this but how can it be downgraded to sell with a price target that's above current market price?
    24 Aug 2013, 02:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs